Massena Memorial Hospital of New York Adopts Masimo Root® and Masimo Patient SafetyNet™

Masimo (NASDAQ: MASI) announced today that Massena Memorial Hospital (MMH) of Massena, New York, has adopted Masimo Root^® and Patient SafetyNet™*. The hospital is integrating Root with wearable rainbow SET™ Pulse CO-Oximeter^® Radius-7^® and Patient SafetyNet to implement a wireless monitoring, patient data automation, and supplemental remote clinician notification system that will be used in all medical-surgical units.

“Massena Memorial Hospital has long been a valued Masimo customer, and with this additional investment, they are continuing to focus on patient safety”

Tweet this

Masimo Patient SafetyNet is a supplemental remote monitoring and clinical notification system that enables information from bedside and tetherless wearable (when used with Radius-7) monitors, which use Masimo SET^® and rainbow^® noninvasive blood constituent monitoring technologies, to be accessible from different locations than patients, and relays alarm notifications to clinicians, wherever they may be. Masimo Measure-through Motion and Low Perfusion™ SET^® pulse oximetry addresses the challenges of low perfusion and motion artifact that limit conventional pulse oximetry, and has been shown to significantly reduce false alarms and increase true alarm detection,¹ helping allow clinicians to focus on the patients and alarms that need the most attention. In 2016, Dartmouth-Hitchcock Medical Center, which has been using Masimo SET^® pulse oximetry and Patient SafetyNet as part of a comprehensive alarm management strategy in all medical-surgical units for ten years, reported achieving a 50% reduction in unplanned ICU transfers and a 60% reduction in rescue events over those ten years, despite increases in patient acuity and occupany.²

Another important feature to MMH is the ability of Root, in conjunction with Patient SafetyNet, to automate the transfer of patient vital signs, including temperature and blood pressure, to the hospital’s Electronic Medical Record (EMR) system, which may help improve nursing workflows.

“The Masimo vital sign monitoring system will provide many benefits to the patients and staff of the Medical/Surgical/Pediatric unit,” said Lisa Susice, MSN, RN, ICU/Med-Surg/Pediatric Nursing Director, MMH. “To be able to combine the ability to monitor our active patients in medical-surgical units reliably with the time-saving ability to transmit pulse rate, temperature, blood pressure, breathing rate, and oxygen saturation values automatically into the patients’ electronic medical records allows our nurses to spend more time nursing our patients, instead of scribing and potentially being delayed in responding to patient alarms. Our staff, who have previously had to manually transcribe the information from the vital sign machine to a paper record, then eventually key it into the electronic record, will save many steps. Additionally, staff will be able to have a quick, real-time glance at each connected patient’s pulse, respirations, and oxygen saturation from monitors strategically placed throughout the floor.”

Ralene North, Chief Nursing Officer, MMH, added, “We are again excited to invest in technology that is focused on patient safety and will improve the working conditions of our nurses. The less time a nurse spends dealing with false alarms or entering data into the system, the more time that can be spent at the bedside attending to the personal and educational needs of the patient.”

Root with Noninvasive Blood Pressure and Temperature is available with Radical-7^® or Radius-7 Pulse CO-Oximeters. Radius-7 provides continuous tetherless wearable monitoring so that patients can have freedom of movement while being monitored. Monitoring parameters from Radical-7 or Radius-7 are sent to Patient SafetyNet through Root, allowing for hospital-wide remote monitoring, automated documentation of patient data in the EMR, and supplemental remote clinician notification of alerts and alarms.

“Massena Memorial Hospital has long been a valued Masimo customer, and with this additional investment, they are continuing to focus on patient safety,” stated Joe Kiani, Founder and CEO of Masimo. “Continuous monitoring in the post-surgical ward has been shown to reduce preventable death.³ In addition, automating the transmission of vital signs data can help to improve workflow and reduce incomplete and erroneous medical records. We applaud Massena Memorial Hospital for leading the way in patient safety.”

MMH is a full-service 50-bed acute-care community hospital located in northern New York with a medical staff of over 50 physicians in over 15 specialties. With more than 400 healthcare employees and 6 outreach clinics, MMH is the second largest employer in the town of Massena.

@MasimoInnovates | #Masimo

*The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

References

1. Shah N et al. Performance of Three New-Generation Pulse Oximeters during Motion and Low Perfusion in Volunteers. J Clin Anesth. 2012 Aug;24(5):385-91.
2. McGrath SP et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
3. Taenzer AH et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.

About Masimo

Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and applications. In 1995, the company debuted Masimo SET^® Measure-through Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. Masimo SET^® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,¹ improve CCHD screening in newborns,² and, when used for continuous monitoring in post-surgical wards, reduce rapid response activations and costs.^3,4,5 Masimo SET^® is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world,⁶including 9 of the top 10 hospitals listed in the 2016-17 U.S. News and World Report Best Hospitals Honor Roll.⁷ In 2005, Masimo introduced rainbow^® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb^®), oxygen content (SpOC™), carboxyhemoglobin (SpCO^®), methemoglobin (SpMet^®), and more recently, Pleth Variability Index (PVi^®) and Oxygen Reserve Index (ORi™), in addition to SpO₂, pulse rate, and perfusion index (PI). In studies with SpHb, reductions in blood transfusion^*were observed^,8,9 and when used with PVi, a reduction in 30-day mortality was observed.¹⁰ In 2014, Masimo introduced Root^®, an intuitive patient monitoring and connectivity platform with the Masimo Open Connect™ (MOC-9™) interface, enabling other companies to augment Root with new features and measurement capabilities. Masimo is also taking an active leadership role in mHealth with products such as the Radius-7™ wearable patient monitor, iSpO₂^® pulse oximeter for smartphones, and the MightySat™ fingertip pulse oximeter. Additional information about Masimo and its products may be found at www.masimo.com. All published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.

*Clinical decisions regarding red blood cell transfusions should be based on the clinician’s judgment considering, among other factors: patient condition, continuous SpHb monitoring, and laboratory diagnostic tests using blood samples.

References

1. Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO₂Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
2. de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;338.
3. Taenzer AH et al. Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers: A Before-And-After Concurrence Study. Anesthesiology. 2010; 112(2):282-287.
4. Taenzer AH et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
5. McGrath SP et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
6. Estimate: Masimo data on file.
7. http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
8. Ehrenfeld JM et al. Continuous Non-invasive Hemoglobin Monitoring during Orthopedic Surgery: A Randomized Trial. J Blood Disorders Transf. 2014. 5:9. 2.
9. Awada WN et al. Continuous and noninvasive hemoglobin monitoring reduces red blood cell transfusion during neurosurgery: a prospective cohort study. J Clin Monit Comput. 2015 Feb 4.
10. Nathan N et al. Impact of Continuous Perioperative SpHb Monitoring. Proceedings from the 2016 ASA Annual Meeting, Chicago. Abstract #A1103.

Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo Root^® and PatientSafetyNet™. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo’s unique noninvasive measurement technologies, including Masimo Root and Patient SafetyNet, contribute to positive clinical outcomes and patient safety; as well as other factors discussed in the “Risk Factors” section of our most recent reports filed with the Securities and Exchange Commission (“SEC”), which may be obtained for free at the SEC’s website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today’s date. We do not undertake any obligation to update, amend or clarify these statements or the “Risk Factors” contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Contacts